Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alefacept.

James Frampton1, Antona Wagstaff

  • 1Adis International Inc., Langhorne, Pennsylvania 19047, USA. demail@adis.com

American Journal of Clinical Dermatology
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Alefacept, a biologic agent targeting T lymphocytes, significantly improved moderate-to-severe psoriasis and quality of life in patients. Treatment demonstrated durable clinical improvements with a safety profile similar to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis.

Dermatology and therapy·2026
Same author

Investigating the effects of mycoprotein and guar gum on postprandial glucose in type 2 diabetes: a double-blind randomised controlled trial.

Nutrition & diabetes·2025
Same author

Effects of Acute Exercise and Carbohydrate Intake on Plasma GDF-15 Levels and Its Association With Appetite Regulation.

Journal of the Endocrine Society·2025
Same author

The impact of acute exercise on appetite regulation: unravelling the potential involvement of gut microbial activity.

The Journal of physiology·2024
Same author

The metabolic interplay between dietary carbohydrate and exercise and its role in acute appetite regulation in males: a randomized controlled study.

The Journal of physiology·2023
Same author

The acute effect of glucagon on components of energy balance and glucose homoeostasis in adults without diabetes: a systematic review and meta-analysis.

International journal of obesity (2005)·2022

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis pathogenesis involves memory-effector CD45RO+ T lymphocytes.
  • Alefacept is a novel biologic agent targeting these specific T lymphocytes.

Purpose of the Study:

  • To evaluate the efficacy and safety of alefacept in patients with moderate-to-severe chronic plaque psoriasis.
  • To assess the impact of alefacept on quality of life.

Main Methods:

  • Placebo-controlled studies involving once-weekly administration of alefacept (7.5mg IV or 15mg IM) for 12 weeks.
  • Assessment of Psoriasis Area and Severity Index (PASI) scores for primary endpoints (>=75% and >=50% improvement).
  • Evaluation of quality of life using patient-reported outcomes.

Related Experiment Videos

Main Results:

  • Approximately 30% of patients achieved >=75% psoriasis improvement after one course, increasing to 40% after a second course.
  • Approximately 55% achieved >=50% improvement after one course, increasing to 70% after a second course.
  • Alefacept responders reported significant improvements in overall health, energy levels, and emotional well-being.

Conclusions:

  • Alefacept is effective in treating moderate-to-severe chronic plaque psoriasis, yielding durable clinical improvements.
  • The treatment significantly enhances the quality of life for responding patients.
  • Alefacept demonstrated a favorable safety and tolerability profile, comparable to placebo, with no reported organ toxicity, disease rebound, or increased risk of infections or malignancies.